Proactively responding to reimbursement reform and the shift in the settlement system

GC Cell said on November 4 that it plans to expand its portfolio of high-value specialized tests and strengthen its business competitiveness through differentiated logistics infrastructure specializing in biopharmaceuticals.


The Ministry of Health and Welfare recently approved, through the Health Insurance Policy Deliberation Committee, a plan to adjust reimbursement rates for specimen tests starting in January 2027 and overhaul the settlement system so that the National Health Insurance Service pays the testing fees directly to both contracting and contracted institutions. The policy is intended to move the market away from price-driven outsourcing practices and toward a focus on quality control and expertise, including testing accuracy and cold-chain transportation.


GC Cell "Strengthening Market Dominance with Specialized Biopharmaceutical Logistics Infrastructure" View original image

In response, GC Cell plans to make active use of its Cellpass and Celltrack logistics infrastructure. Cellpass provides comprehensive supply chain management services (3PL/4PL), while Celltrack is a high-value biopharmaceutical logistics solution that uses temperature-controlled vehicles and its proprietary G-Hub monitoring system to ensure real-time temperature monitoring and location tracking throughout the entire process.


GC Cell also plans to work with GC Labs to increase the share of high-value, technically demanding specialized tests that are less affected by reimbursement rate cuts and have high technical barriers to entry, including next-generation sequencing (NGS) and tests for rare and endocrine diseases.



GC Cell CEO Kim Jaewang said, "We will continue to maintain our specimen testing services and biopharmaceutical logistics businesses as stable sources of cash flow, while ensuring the smooth expansion of our cell and gene therapy (CGT) research and development and global contract development and manufacturing (CDMO) businesses."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing